Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow

Denali Therapeutics secured FDA approval for AVLAYAH, a novel enzyme replacement therapy for Hunter Syndrome, a rare lysosomal storage disorder, marking a major milestone in rare disease treatment. The company outlined commercial launch plans for AVLAYAH, targeting Q2 2026, with a focus on rapid market penetration and patient access through specialized distribution networks. Clinical trials demonstrated AVLAYAH’s superior efficacy in reducing disease biomarkers compared to existing therapies, with a favorable safety profile in pediatric and adult patients. Denali emphasized its manufacturing readiness, scaling up production at its California facility to meet anticipated demand, ensuring supply chain resilience for global distribution. Investor presentations highlighted AVLAYAH’s potential as a blockbuster therapy, projecting peak sales of over $1 billion annually, driven by its first-in-class mechanism and unmet medical need.